Skip to Content
Merck
  • Plasma concentrations of CCL3 and CCL4 in the cardiac and digestive clinical forms of chronic Chagas disease.

Plasma concentrations of CCL3 and CCL4 in the cardiac and digestive clinical forms of chronic Chagas disease.

Cytokine (2016-12-22)
Amanda Priscila de Oliveira, Christiane Maria Ayo, Kallyne Kioko Oliveira Mimura, Sonia Maria Oliani, Cássia Rubia Bernardo, Ana Vitória Silveira Camargo, Luís Sérgio Ronchi, Aldenis Albaneze Borim, Eumildo de Campos Júnior, Cinara Cássia Brandão de Mattos, Lilian Castiglioni, Reinaldo Bulgarelli Bestetti, Carlos Eugênio Cavasini, Luiz Carlos de Mattos
PMID28002786
ABSTRACT

The aim of this study was to investigate the plasma levels of the CCL3 and CCL4 chemokines in patients with the cardiac and digestive clinical forms of chronic Chagas disease and in cardiac patients with and without left ventricular systolic dysfunction (LVSD). Plasma samples from 75 patients were evaluated by enzyme-linked immunosorbent assay (ELISA) to confirm infection by T. cruzi. Plasma levels of the CCL3 and CCL4 chemokines were measured using Milliplex® MAP assay (Millipore). There were no significant differences in the levels of CCL3 and CCL4 between patients with the digestive and cardiac clinical forms of Chagas disease. Moreover, no significant differences were found between patients without LVSD and those with LVSD. Higher CCL3 and CCL4 plasma levels were found in patients with LVSD compared to those with the digestive form of the disease. The CCL3 and CCL4 chemokines might not be involved in differential susceptibility to the digestive and cardiac clinical forms of chronic Chagas disease, and it seems they do not influence the development of LVSD.